Inflammation-related nomogram for predicting survival of patients with unresectable hepatocellular carcinoma received conversion therapy

doi:10.3748/wjg.v29.i20.3168

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 20

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4551)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-7) series, Tables (1-1) series.

Item

Count

PDF

WORD

HTML

1932

Figures (1-7)

360

Tables (1-1)

347

Sum=2752

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

147

Download

590

Sum=737

Publishing Process of This Article

Item

Count

Browse

182

Download

768

Sum=950

May 28, 2023 (publication date) through Nov 27, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. May 28, 2023; 29(20): 3168-3184
Published online May 28, 2023. doi: 10.3748/wjg.v29.i20.3168

Full Size Figure Download Figure

Figure 1 Overall survival for unresectable hepatocellular carcinoma patients accepted conversion therapy. A: Entire cohort; B: Training cohort; C: Validation cohort.

Citation: Wu JL, Luo JY, Jiang ZB, Huang SB, Chen GR, Ran HY, Liang QY, Huang MS, Lai LS, Chen JW. Inflammation-related nomogram for predicting survival of patients with unresectable hepatocellular carcinoma received conversion therapy. World J Gastroenterol 2023; 29(20): 3168-3184
URL: https://www.wjgnet.com/1007-9327/full/v29/i20/3168.htm
DOI: https://dx.doi.org/10.3748/wjg.v29.i20.3168